Haplo-HSCT is Superior to Chemotherapy for Standard Risk ALL in CR1—Results of Prospective Multicenter Trial (NCT02042690)
Meng Lv,Xiao-jun Huang,Qian Jiang,Hao Jiang,Xiao-hui Zhang,Lan-ping Xu,Yu Wang,Ying-Jun Chang,Kai-yan Liu,Dao-bin Zhou,Yu Hu,Depei Wu,Dai-hong Liu
DOI: https://doi.org/10.1016/j.bbmt.2018.12.072
2019-01-01
Biology of Blood and Marrow Transplantation
Abstract:BackgroundIn the present prospective multicenter trial (NCT02042690), we investigated whether haplo-HSCT has a favorable impact on survival as post remission treatment for standard risk acute lymphoblastic leukemia (ALL) patients in the first complete remission (CR1) by comparing with chemotherapy alone.Methods£°Inclusion criteria of ALL:(1) age 18 to 39 years; (2) without high-risk features, which consisted of elevated WBC count(>30 *109/L for B cell lineage or >100 *109/L for T cell lineage), or high-risk cytogenetic abnormalities, determined according to the National Comprehensive Cancer Network 2013 guidelines; and (3) achieving CR after 1 to 2 cycles of induction. Subjects without a suitable HLA matched sibling (MSD) or HLA-matched unrelated donor (¡Ý8/10 URD) after 2 cycles of consolidation (Hyper-CVAD B/A*1) were eligible for haplo-HSCT or further chemotherapy (Hyper-CVAD B/A*3). Landmark analysis (4 months after CR1) was used when comparing the outcomes of patients receiving haplo-HSCT vs. chemotherapy. A propensity score (PS) was calculated using multivariable logistic regression for each individual. The hazard ratios (HRs) for Leukemia-free survival (LFS), overall survival (OS), cumulative incidence of relapse(CIR), and nonrelapse mortality(NRM) were adjusted with PS.ResultsNewly diagnosed standard risk ALL patients meeting inclusion criteria (n=112) were consecutively enrolled at 5 centers including Peking University People¡¯s Hospital, Peking Union Hospital, Wuhan Union Hospital, First Hospital of Soochow University and General Hospital of PLA and between July 2014 and June 2017, with median follow-up 24.6 months. Patients were excluded in final analysis: 1) early relapse (n=6) within 4 months after CR1; 2) MSD-HSCT (n=16) or URD-HSCT (n=1). The remaining patients (n=89) either received haplo-HSCT (n=49) or chemotherapy (n=40). The 2-year LFS (70.5 [54.2-81.9]% vs 41.4[25.9-56.2]%, p=0.0073) and 2-year OS (81.3 [65.5-91.4]% vs 51.2[33.8-66.1]%, p=0.0073) of the Haplo-HSCT group was significantly higher than the chemotherapy group. In the multivariate analysis with propensity score adjustment, postremission treatment (haplo-HSCT vs chemotherapy) was an independent risk factor affecting the LFS (HR 0.388, 95% CI 0.172-0.873, P=0.022), OS (HR 0.346, 95% CI 0.156-0.140-0.853, P=0.003) and CIR(HR 0.247, 95% CI 0.098-0.624, P=0.003); Positive minimal residual disease after the first consolidation was an independent risk factor for LFS (HR 2.162, 95% CI 0.973-4.803, P=0.027) and CIR (HR 3.667, 95% CI 1.445-9.302, P=0.006). Diagnosis (T vs B) was an independent risk factor for OS(HR2.267, 95% CI 1.493-3.442, P=0.021).ConclusionsOur results suggest that Haplo-HSCT is superior to chemotherapy alone as post-remission treatment for in adult patients (age 18-39) with standard risk ALL in CR1. In the present prospective multicenter trial (NCT02042690), we investigated whether haplo-HSCT has a favorable impact on survival as post remission treatment for standard risk acute lymphoblastic leukemia (ALL) patients in the first complete remission (CR1) by comparing with chemotherapy alone. £°Inclusion criteria of ALL:(1) age 18 to 39 years; (2) without high-risk features, which consisted of elevated WBC count(>30 *109/L for B cell lineage or >100 *109/L for T cell lineage), or high-risk cytogenetic abnormalities, determined according to the National Comprehensive Cancer Network 2013 guidelines; and (3) achieving CR after 1 to 2 cycles of induction. Subjects without a suitable HLA matched sibling (MSD) or HLA-matched unrelated donor (¡Ý8/10 URD) after 2 cycles of consolidation (Hyper-CVAD B/A*1) were eligible for haplo-HSCT or further chemotherapy (Hyper-CVAD B/A*3). Landmark analysis (4 months after CR1) was used when comparing the outcomes of patients receiving haplo-HSCT vs. chemotherapy. A propensity score (PS) was calculated using multivariable logistic regression for each individual. The hazard ratios (HRs) for Leukemia-free survival (LFS), overall survival (OS), cumulative incidence of relapse(CIR), and nonrelapse mortality(NRM) were adjusted with PS. Newly diagnosed standard risk ALL patients meeting inclusion criteria (n=112) were consecutively enrolled at 5 centers including Peking University People¡¯s Hospital, Peking Union Hospital, Wuhan Union Hospital, First Hospital of Soochow University and General Hospital of PLA and between July 2014 and June 2017, with median follow-up 24.6 months. Patients were excluded in final analysis: 1) early relapse (n=6) within 4 months after CR1; 2) MSD-HSCT (n=16) or URD-HSCT (n=1). The remaining patients (n=89) either received haplo-HSCT (n=49) or chemotherapy (n=40). The 2-year LFS (70.5 [54.2-81.9]% vs 41.4[25.9-56.2]%, p=0.0073) and 2-year OS (81.3 [65.5-91.4]% vs 51.2[33.8-66.1]%, p=0.0073) of the Haplo-HSCT group was significantly higher than the chemotherapy group. In the multivariate analysis with propensity score adjustment, postremission treatment (haplo-HSCT vs chemotherapy) was an independent risk factor affecting the LFS (HR 0.388, 95% CI 0.172-0.873, P=0.022), OS (HR 0.346, 95% CI 0.156-0.140-0.853, P=0.003) and CIR(HR 0.247, 95% CI 0.098-0.624, P=0.003); Positive minimal residual disease after the first consolidation was an independent risk factor for LFS (HR 2.162, 95% CI 0.973-4.803, P=0.027) and CIR (HR 3.667, 95% CI 1.445-9.302, P=0.006). Diagnosis (T vs B) was an independent risk factor for OS(HR2.267, 95% CI 1.493-3.442, P=0.021). Our results suggest that Haplo-HSCT is superior to chemotherapy alone as post-remission treatment for in adult patients (age 18-39) with standard risk ALL in CR1.